Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.

Jones CK, Engers DW, Thompson AD, Field JR, Blobaum AL, Lindsley SR, Zhou Y, Gogliotti RD, Jadhav S, Zamorano R, Bogenpohl J, Smith Y, Morrison R, Daniels JS, Weaver CD, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR
J Med Chem. 2011 54 (21): 7639-47

PMID: 21966889 · PMCID: PMC3226828 · DOI:10.1021/jm200956q

There is an increasing amount of literature data showing the positive effects on preclinical antiparkinsonian rodent models with selective positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)). However, most of the data generated utilize compounds that have not been optimized for druglike properties, and as a consequence, they exhibit poor pharmacokinetic properties and thus do not cross the blood-brain barrier. Herein, we report on a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides with improved PK properties with excellent potency and selectivity as well as improved brain exposure in rodents. Finally, ML182 was shown to be orally active in the haloperidol induced catalepsy model, a well-established antiparkinsonian model.

MeSH Terms (18)

Administration, Oral Allosteric Regulation Animals Antiparkinson Agents Biological Availability Catalepsy CHO Cells Cricetinae Cricetulus Haloperidol Humans In Vitro Techniques Isoindoles Microsomes, Liver Picolinic Acids Rats Receptors, Metabotropic Glutamate Structure-Activity Relationship

Connections (2)

This publication is referenced by other Labnodes entities:

Links